Buprenorphine: Effective treatment of opioid addiction starts in the office

American Family Physician

Volumn 73, Issue 9, 2006, Pages 1513-1516

  Fiellin, David A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Physician Clinical Support System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; OPIATE;

DRUG BIOAVAILABILITY; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG WITHDRAWAL; EDITORIAL; GENETIC PREDISPOSITION; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE DEFICIENCY; OPIATE ADDICTION; PATIENT EDUCATION; PHYSICIAN; PRESCRIPTION; RELAPSE; RISK FACTOR;

AMBULATORY CARE; BUPRENORPHINE; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 33744461533     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Fiellin DA, Butler R, D'Onofrio G, Brown RL, O'Connor PG. The physician's role in caring for patients with substance use disorders: implications for medical education and training. Substance Abuse 2002;23:207-22.
2. Donaher PA, Welsh C. Managing opioid addiction with buprenorphine. Am Fam Physician 2006;73:1573-8, 1580.
3. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 2006;81:103-7.
4. Cami J, Farre M. Drug addiction. N Engl J Med 2003;349:975-86.
5. U.S. Department of Health and Human Services. Results from the 2002 national survey on drug use and health: national findings. Accessed online March 6, 2006, at: http://www.oas.samhsa.gov/nhsda/2k2nsduh/Results/2k2Results.htm.
6. U.S. Department of Health and Human Services. National survey of drug use and health. Nonmedical use of prescription pain relievers. Accessed online March 6, 2006, at: http://www.oas.samhsa.gov/2k4/pain/pain.pdf.
7. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Teen drug use down but progress halts among youngest teens [press release]. Ann Arbor: University of Michigan News and Information Services; December 19, 2005. Accessed online March 6, 2006, at: http://www.monitoringthefuture.org/data/05data.html#2005data- drugs.
8. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002209.
9. Carroll KM, Schottenfeld R. Nonpharmacologic approaches to substance abuse treatment. Med Clin North Am 1997;81:927-44.
10. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend 2005;79:113-6.
11. McLeod CC, WB Kissin, Stanton A, Sonnefeld J. 30-day outcomes for buprenorphine patients treated by a national sample of qualified physicians. Findings from the Center for Substance Abuse Treatment's evaluation of the Buprenorphine Waiver Program. Accessed online, March 13, 2006, at: http://www.buprenorphine.samhsa.gov/findings.pdf.
12. Cicero TJ, Inciardi JA. Potential for abuse of buprenorphine in office-based treatment of opioid dependence. N Engl J Med 2005;353:1863-5.
13. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med 2002;347:817-23.